Regeneron Pharmaceuticals Inc

Dupixent gets Japanese approval for 6‑11‑year‑olds with severe asthma, backed by phase‑three data showing reduced exacerbations and better lung function, boosting Regeneron’s pediatric biologic portfolio.

Regeneron’s JPMHC appearance highlights new COVID‑19, cancer and gene‑editing breakthroughs, showing strong efficacy, safety and growth prospects.

Regeneron faces analyst downgrades while securing a 2026 biosimilar license with Alvotech and Teva to protect its eye‑care lead, navigating pricing and patent pressures.

Regeneron’s analyst downgrade signals looming biosimilar pressure, yet the company’s Alvotech‑Teva licensing deal for an Eylea biosimilar may boost revenue, lower costs, and secure market share by Q4 2026.

Regeneron’s upcoming investor conferences reveal new Dupixent data, expanded approvals, and strategic plans—key insights for analysts and healthcare investors.

Regeneron Pharmaceuticals has announced positive results from two Phase 3 clinical trials, one for a novel obesity treatment and the other for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder, marking significant milestones in th…

Regeneron Pharmaceuticals Inc has announced significant advancements in its oncology portfolio, including positive five-year follow-up data for its Libtayo treatment in advanced non-small cell lung cancer, and a definitive settlement with Sandoz to …

Regeneron Pharmaceuticals has made significant breakthroughs in treating rare diseases, including a promising new therapy for generalized myasthenia gravis and a RNA drug for a rare autoimmune disease, with positive trial data expected to lead to FD…

Regeneron Pharmaceuticals has announced a groundbreaking success in its Phase 3 trial for Generalized Myasthenia Gravis, leading to a surge in stock price and market capitalization.

Regeneron Pharmaceuticals Inc is poised for continued growth, driven by its innovative pipeline and strong track record of delivering results, with analysts maintaining or initiating buy ratings and price targets exceeding the current market value.